, first-generation TKIs, had been looked at in the adjuvant space where they prolonged disease-free survival but did not prolong overall survival.
We have a significant survival benefit at this point in time, but will that also be clearly attenuated, starting with another 9 or 12 months of follow-up?I agree. You can see the shape of the disease-free survival curves. They absolutely do begin to come together, mirroring what we've seen in older drugs after that end of 3-year treatment.
Aspirationally, while we may need to apply these new data to most patients now, I hope in the future that we will use more dynamic measures to predict better who truly needs this therapy.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: